[Skip to Content]
[Skip to Content Landing]
Views 315
Citations 0
April 23, 2018

Controversies and Future Directions of Ocular Biomarkers in Alzheimer Disease

Author Affiliations
  • 1Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina
  • 2Division of Translational Neuroscience, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina
JAMA Neurol. Published online April 23, 2018. doi:10.1001/jamaneurol.2018.0602

Alzheimer Disease (AD) is the most common form of dementia.1 There is currently no cure for the disease, and available treatments to relieve symptoms are moderately beneficial at best. The hallmark pathologic feature of AD involves the progressive accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in the brain.2 Drug development for the prevention of AD has been hampered by the lack of fully validated biomarkers of early disease.

First Page Preview View Large
First page PDF preview
First page PDF preview